Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | KIF11 | P52732 | 8/20 | 0.50 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8990753 | 0.98 | MAOB (0.61) | MAOBTAAR1KIF11FDFT1MIF | |
| SCHEMBL1696674 | 0.94 | TAAR1 (0.61) | MAOBTAAR1MIFIDO1DAO | |
| Ammonia Solution, Strong SCHEMBL6193177 | 0.91 | TAAR1 (0.59) | MAOBTAAR1MIFIDO1DAO | |
| SCHEMBL10381413 | 0.88 | MAOB (0.59) | MAOBTAAR1KIF11FDFT1 | |
| SCHEMBL17108417 | 0.86 | MAOB (0.58) | MAOBTAAR1FDFT1 | |
| SCHEMBL8990675 | 0.86 | MAOB (0.58) | MAOBTAAR1KIF11FDFT1DAO | |
| SCHEMBL10382748 | 0.86 | MAOB (0.58) | MAOBTAAR1FDFT1 | |
| SCHEMBL9075469 | 0.86 | MAOB (0.47) | MAOBTAAR1KIF11FDFT1 | |
| SCHEMBL8990814 | 0.86 | MAOB (0.61) | MAOBTAAR1KIF11FDFT1MIF | |
| SCHEMBL10381425 | 0.85 | MAOB (0.56) | MAOBTAAR1FDFT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-02-15 | — | — | US | disclosed |
| EP-0427829-A1 | TRIFLUOROTOLUOL COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GmbH (DE) | 1991-05-22 | — | — | EP | disclosed |
| WO-1990014404-A1 | TRIFLUOROTOLUOL COMPOUNDS AND LIQUID CRYSTALLINE MEDIUM | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1990-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180044343-A1 | BICYCLIC IMIDAZOLO DERIVATIVE | PDE3A, PDE2A, PDE5A | MAOB 210/4885TAAR1 3386/4885KIF11 2743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.